Key result
Amiodarone causes thyroid dysfunction in 15-20% of patients, requiring structured monitoring and phenotype-directed management to preserve arrhythmia control.
Why the study?
Amiodarone is an effective antiarrhythmic agent but causes thyroid dysfunction in 15-20% of patients, leading to amiodarone-induced hypothyroidism and thyrotoxicosis.
How should amiodarone-associated thyroid dysfunction be managed in clinical practice?
How should amiodarone-associated thyroid dysfunction be managed in clinical practice?
This review provides a practical, guideline-based framework for managing amiodarone-induced thyroid dysfunction, emphasizing that arrhythmia control can often be preserved through phenotype-directed thyroid therapy.
Answers are grounded in this paper and cite their sources.
Reinforces tailored amiodarone thyroid management in practice; leaves open need for prospective trials to validate protocols.
BACKGROUND: Amiodarone is an effective antiarrhythmic agent but causes thyroid dysfunction in 15-20% of patients, resulting in amiodarone-induced hypothyroidism (AIH) and thyrotoxicosis (AIT). METHODS: We performed a narrative review of randomized trials, prospective cohort studies, systematic reviews, and major guideline documents. PubMed and Embase were searched from January 2000 to December 2024 using terms related to amiodarone, thyroid dysfunction, thyrotoxicosis, and hypothyroidism. Priority was given to higher-quality evidence and contemporary society guidelines, including those from the ACC/AHA, ESC, ETA, and ATA. RESULTS: AIH is generally managed with levothyroxine without routine amiodarone discontinuation. AIT requires phenotypic differentiation and phenotype-directed therapy, with corticosteroids preferred for Type 2 AIT and antithyroid drugs for Type 1 AIT. Decisions regarding amiodarone continuation should be individualized according to thyroid and cardiac risk. CONCLUSIONS: Baseline screening, structured monitoring, and phenotype-directed management allow effective treatment of amiodarone-associated thyroid dysfunction while preserving arrhythmia control.
No takes yet. Share an insight, caveat, or question.
Nagesh et al. (2026) conducted a review in Amiodarone-associated thyroid dysfunction. Amiodarone was evaluated. Amiodarone causes thyroid dysfunction in 15-20% of patients, requiring structured monitoring and phenotype-directed management to preserve arrhythmia control.
Synapse has enriched 10 related papers. Consider them for comparative context: